Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine
Part of paid clinical trials in Mobile, Alabama.
- Sponsor
- Pfizer
- Study ID
- NCT00072852
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Irinotecan — DRUG
Study Details
The purpose of this phase II, randomized, open-label clinical trial is to study 2 schedules of single-agent Irinotecan in women with metastatic breast cancer who have experienced failure of prior therapy with an anthracycline, a taxane, and capecitabine. Patients will receive Irinotecan capsules either once each day for 5 days, or once a day for 14 days in 3 week cycles.
Key Dates
- Start date
- Nov 30, 2003
- Status verified
- Oct 2008
- Primary completion
- May 31, 2007
- Completion
- May 31, 2007
Study Design
- Enrollment
- 134 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Primary Outcome Measure
To evaluate the safety and efficacy of Irinotecan in refractory breast cancer.
Locations (57)
Find similar trials in Mobile, AL
By condition
By specialty
Related Studies
- Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer CellsRecruiting · Washington University School of Medicine · St Louis, Missouri
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPHASE2 · Recruiting · QuantumLeap Healthcare Collaborative · Birmingham, Alabama
- Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence ScorePHASE2 · Recruiting · Washington University School of Medicine · St Louis, Missouri
- A Registry Study of Breast Microseed TreatmentRecruiting · Concure Oncology-Breast Microseed Inc. · Pittsburgh, Pennsylvania